DS 1501
Alternative Names: Anti-siglec-15-antibody-Daiichi-Sankyo; DS-1501a; DS1501; Siglec-15 AbLatest Information Update: 28 Oct 2020
At a glance
- Originator Daiichi Sankyo Company
- Class Antibodies; Osteoporosis therapies
- Mechanism of Action Siglec-15 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in Japan (SC)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Osteoporosis in USA (SC)
- 23 Jan 2018 3297334 - Updated KDM and scientific section (PD). HE already present